JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Transcript
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JB Chemicals reported Q4 FY25 revenue of INR949 crore (up 10% YoY), operating EBITDA of INR240 crore (up 15%), and net profit of INR146 crore (up 15%). Operating EBITDA margin expanded 90 bps to 25.3%, with gross margin at 66.1%. For full-year FY25, revenue grew 12% to INR3,918 crore and net profit rose 19% to INR660 crore, with ROC at 32% and net cash position improving to INR689 crore from INR107 crore. Management raised operating EBITDA margin guidance to 27%-29% for the third consecutive year and expects 30-50 bps gross margin improvement in FY26, supported by cost initiatives and a richer chronic mix in the domestic business. The CDMO business is expected to scale to an INR150 crore quarterly run-rate from INR110 crore as new marquee projects (lozenges, ORS solutions, throat sprays, iodine formulations) commercialize over the next 12-18 months.
Strong quarterly performance, a third consecutive margin guidance hike, and a healthy INR689 crore net cash balance signal improving earnings quality and capital strength for shareholders. With the ophthal perpetual license triggering in December 2026 and new CDMO projects ramping up, margin upside beyond current guidance appears possible, supporting a positive medium-term outlook.